Q: Is there a Hyalo tirzepatide recall?

What patients reported about Hyalo tirzepatide vials

A:No, patient reports through October 2026 describe no formal recall of Hyalo tirzepatide, though users flagged problems in several of its lots. One commenter on a Hyalo thread wrote that "no recall was issued" and called that in itself the key problem.¹ The Class II recall in the news that month involved Apothecary, and one commenter said Hyalo "seems to be sailing through" the complaints about its vials.²

Patients holding Hyalo vials to bright light reported floating particles and thin, fiber-like strands in lots HT-021 and HT-023. One patient had already used some medication before seeing the problem, and NewLife Rx sent a prepaid label so the vials could go back to Hyalo for investigation.³ Another buyer received a full refund from Hyalo for an order of Hyalo vials placed through Gimmecare.⁴

A Class II recall like Apothecary's runs at the retail level, so patients can keep using the drug unless the recalling company or the FDA says otherwise, according to FDA guidance quoted on the forum. One patient's telehealth notice said the Apothecary recall affected only vials labeled Apothecary Pharma.⁵ On our reading, a practice dispensing compounded tirzepatide should check its lot numbers and tell patients which pharmacy filled their vials. For more about what the FDA has found, see our compounded injectable risk.